170 results
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
19 Apr 24
Current report (foreign)
6:12am
achieved long-term clinical remission,” said Timothy Ritter, MD, senior medical director, Department of Research and Education, GI Alliance Research … maintenance therapy administered every 2 weeks achieved long-term clinical remission*** compared to patients receiving placebo (48% vs. 34%; p<0.01
6-K
TAK
Takeda Pharmaceutical Co
9 Feb 24
Current report (foreign)
6:03am
and clinically meaningful, consistent with the primary endpoint. The majority of patients who completed the trial entered a long-term extension study … or in the ongoing TAK-861 long-term extension trial.
“We are thrilled to announce these clear and compelling results from the TAK-861 trial in narcolepsy
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
and mid- to long-term sustained growth of the company. Once first approval of a product is achieved, Takeda R&D is equipped to support geographic … as long-term data on TAK-755 prophylaxis from a Phase 3b continuation study at the International Society on Thrombosis and Haemostasis (ISTH) 2023
6-K
TAK
Takeda Pharmaceutical Co
1 Feb 24
Current report (foreign)
6:06am
financing activities:
Net increase in short-term loans and commercial papers
Proceeds from issuance of bonds and long-term loans
Repayments of bonds … and long-term loans
Proceeds from the settlement of cross currency interest rate swaps related to bonds
Acquisition of treasury shares
Interest paid
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
1 Feb 24
Current report (foreign)
6:06am
investors may consider to be unrelated to our long-term operations. These non-IFRS measures are not, and should not be viewed as, substitutes for IFRS … long-term loans
Adjusted EBITDA (LTM)*4
Repayment of long-term loans
Repayment of bonds
Proceeds from the settlement of cross currency interest rate
6-K
EX-99.1
vs2 5ez4b9zqma
14 Dec 23
Current report (foreign)
6:01am
6-K
EX-99.1
fwyx3v9fsf1 pobs
30 Nov 23
Current report (foreign)
6:01am
6-K
EX-99.1
6esefo3uc5eqven
30 Oct 23
Current report (foreign)
6:02am
6-K
tmihh0 9r3
30 Oct 23
Current report (foreign)
6:02am
6-K
EX-99.1
ji27jh
26 Oct 23
Current report (foreign)
6:20am
6-K
s8ad6dss8nrw j54su7z
26 Oct 23
Current report (foreign)
6:20am
6-K
EX-99.1
naanfncruth wfjkm
18 Oct 23
Current report (foreign)
6:20am
6-K
74n3rzb9r0xntp
1 Aug 23
Current report (foreign)
6:10am
6-K
mzx59
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
6e0h43s gk
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
ys5xw24yx8ycpyq by
12 Jul 23
Current report (foreign)
6:07am
6-K
EX-99.1
neq4aytw8bim6d0l
6 Jul 23
Current report (foreign)
6:18am
S-8
4kwjanjv lpwwoa
28 Jun 23
Registration of securities for employees
6:35am
S-8
EX-5.1
068 717618t
28 Jun 23
Registration of securities for employees
6:35am
S-8
EX-99.2
q1jkm94psj2nkj39p
28 Jun 23
Registration of securities for employees
6:35am